Aljian Capital Management LLC Grows Holdings in Amgen Inc. (NASDAQ:AMGN)

Aljian Capital Management LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 398.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 6,052 shares of the medical research company's stock after buying an additional 4,837 shares during the period. Amgen accounts for approximately 0.5% of Aljian Capital Management LLC's holdings, making the stock its 29th biggest position. Aljian Capital Management LLC's holdings in Amgen were worth $1,950,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Hillsdale Investment Management Inc. grew its position in shares of Amgen by 44.3% during the first quarter. Hillsdale Investment Management Inc. now owns 1,400 shares of the medical research company's stock valued at $398,000 after purchasing an additional 430 shares in the last quarter. PYA Waltman Capital LLC grew its holdings in Amgen by 16.4% during the 1st quarter. PYA Waltman Capital LLC now owns 9,541 shares of the medical research company's stock valued at $2,713,000 after buying an additional 1,347 shares in the last quarter. Bessemer Group Inc. increased its stake in Amgen by 29.3% in the 1st quarter. Bessemer Group Inc. now owns 37,202 shares of the medical research company's stock worth $10,578,000 after acquiring an additional 8,441 shares during the last quarter. Arjuna Capital raised its holdings in shares of Amgen by 58.3% during the 1st quarter. Arjuna Capital now owns 24,142 shares of the medical research company's stock worth $6,864,000 after acquiring an additional 8,893 shares in the last quarter. Finally, Lake Street Advisors Group LLC boosted its position in shares of Amgen by 240.8% during the 1st quarter. Lake Street Advisors Group LLC now owns 12,755 shares of the medical research company's stock valued at $3,626,000 after acquiring an additional 9,012 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Trading Down 0.9 %

Shares of NASDAQ AMGN traded down $2.58 during trading on Monday, hitting $278.76. 3,174,632 shares of the company traded hands, compared to its average volume of 2,456,979. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a market capitalization of $149.84 billion, a P/E ratio of 35.69, a P/E/G ratio of 2.53 and a beta of 0.60. The company has a 50-day moving average price of $319.90 and a 200-day moving average price of $318.65. Amgen Inc. has a 1 year low of $260.52 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same period in the prior year, the firm posted $4.96 earnings per share. The firm's revenue was up 23.2% on a year-over-year basis. On average, equities analysts predict that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be issued a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 3.23%. Amgen's payout ratio is currently 115.24%.

Analysts Set New Price Targets

AMGN has been the topic of several research reports. Robert W. Baird restated an "underperform" rating and issued a $215.00 price target on shares of Amgen in a research report on Wednesday, September 25th. William Blair restated an "outperform" rating on shares of Amgen in a research report on Tuesday, November 12th. Truist Financial lowered Amgen from a "buy" rating to a "hold" rating and lifted their price target for the stock from $320.00 to $333.00 in a research report on Monday, October 14th. Royal Bank of Canada restated an "outperform" rating and set a $362.00 price objective on shares of Amgen in a research report on Thursday, September 26th. Finally, Bank of America lifted their target price on Amgen from $325.00 to $330.00 and gave the stock a "neutral" rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Amgen has a consensus rating of "Moderate Buy" and an average price target of $333.57.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.